TSX VENTURE EXCHANGE - NEX · NGEN
-7.93% · -$0.1800 · Vol 608.5K
Market closed · last close 4:00 PM ET · price as of 19:25:00 ET
NervGen Pharma Corp

NervGen Pharma Corp

Pharmaceuticals
$2.09
Card
Relationship Map

Follow $NGEN

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $NGEN by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
NGEN
NervGen Pharma Corp
Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Lowest range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

26/ 100
Veridion Score
Lowest range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is NGEN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading NGEN catalysts
About NervGen Pharma Corp
Pharmaceuticals
Listed since
2019
Employees
9
Country
CA

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.27
Day high
$2.27
Day low
$2.04
Previous close
$2.27
52W high
$5.97
-64.99% from high
52W low
$1.59
11% of range
Market cap
$220.4M
EPS
$-0.3622
Beta
1.16
Shares out
107.5M
Volume
608.5K
1.06× rel vol
Avg volume
572.5K
VWAP
$2.11
Price history computed in-house
1W
-4.35%
1M
+12.37%
3M
-2.34%
SMA 50 $1.90 · above
SMA 200 Not reported · Not reported
52W position 11%

NGEN overview

Veridion Score
26
Registered · 2026-09-18
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around NGEN.Congress disclosuresOpen receipt and filing context for NGEN.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading NGEN Form 4 filings
Public disclosures

Congress activity in NGEN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for NGEN in the cached public ledger.

Federal contracts

NGEN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NGEN in this window.
Lobbying spend

NGEN lobbying filings, year to date.

Registered lobbying filings matched to NervGen Pharma Corp.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NGEN in this window.
Loading news for NGEN
Analyst ratings
Sovereign unlock shows live analyst consensus for NGEN.
Options
Sovereign unlock shows live options positioning for NGEN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.